Protein Kinase Inhibitors: all 15,278 studies that test it

Page 113 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorTerminatedNCT02673736Phase 1
• Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerCompletedNCT02672475Phase 1
• Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCWithdrawnNCT02672358Phase 2
• A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma PatientsStatus unknownNCT02671513Phase 1
• Conversion to Sirolimus: Effects in Cytomegalovirus Infection RecurrenceStatus unknownNCT02671318Phase 4
• Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
• Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2
• A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyCompletedNCT02670044Phase 1
• PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaCompletedNCT02669511Phase 2
• Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) PatientsStatus unknownNCT02665910Phase 1
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand EczemaCompletedNCT02664805Phase 2
• A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon CancerTerminatedNCT02664077Phase 3
• Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
• Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02659241Early Phase 1
• SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsCompletedNCT02657122Phase 1
• BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsWithdrawnNCT02656849Phase 2
• Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialStatus unknownNCT02655536Phase 2
• Hematopoietic Stem Cell Transplant Survivors StudyCompletedNCT02652052Phase 1
• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingNCT02650401Phase 1/2
• Study of Metatinib Tromethamine TabletStatus unknownNCT02650375Phase 1
• Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
• Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationTerminatedNCT02649751Phase 2
• Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Phase 2
• Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid LevelsCompletedNCT02648269Phase 1
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
• Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02645981Phase 2/3
• Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell CarcinomaCompletedNCT02645864Phase 1
• Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic MelanomaCompletedNCT02645149Phase 2
• Abemaciclib in Children With DIPG or Recurrent/Refractory Solid TumorsCompletedNCT02644460Phase 1
• A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
• Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal MalignanciesTerminatedNCT02638909Phase 2
• Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTCompletedNCT02638766Phase 2
• Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs TherapyCompletedNCT02638467Phase 2
• Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
• A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy AdultsCompletedNCT02638116Phase 1
• A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenActive, not recruitingNCT02637687Phase 1/2
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
• Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation StudyCompletedNCT02636426Phase 1
• Phase I Dose Escalation Study for VIP152 in Patients With Advanced CancerCompletedNCT02635672Phase 1
• Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02635074Phase 1
• A Study of LY2880070 in Participants With Advanced or Metastatic CancerCompletedNCT02632448Phase 1/2
• A Study of HMPL-689 in Healthy VolunteersCompletedNCT02631642Phase 1
• Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2
• Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal CancerWithdrawnNCT02630420Phase 1
• Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory CancerCompletedNCT02630199Phase 1
• Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02629848Phase 3
• Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02629809Phase 2
• Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNACompletedNCT02629523Phase 2
• High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseActive, not recruitingNCT02629120Phase 1/2
• Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)CompletedNCT02626884Phase 2
• A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian PopulationTerminatedNCT02626754Phase 2
• Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStatus unknownNCT02626507Phase 1
• Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene AmplificationCompletedNCT02626364Phase 2
• A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02626234Phase 1
• Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLCCompletedNCT02625168Phase 2
• Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.CompletedNCT02624557Phase 1
• A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic CarcinomaCompletedNCT02623127Phase 2
• Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS LymphomaStatus unknownNCT02623010Phase 2
• A Multiple Dose Study of DWP10292 and UDCA in Healthy Male SubjectsCompletedNCT02622685Phase 1
• Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor MalignanciesTerminatedNCT02620839Phase 1
• mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma MultiformeCompletedNCT02619864Phase 1
• Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast CancerWithdrawnNCT02619669Phase 1
• Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal CancerStatus unknownNCT02619435Phase 2
• Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and PharmacodynamicsCompletedNCT02619162Phase 1
• Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedNCT02617277Phase 1
• Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast CancersStatus unknownNCT02616848Phase 1
• Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101TerminatedNCT02616055Phase 2
• PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric AdenocarcinomaCompletedNCT02615730Phase 1/2
• Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDCompletedNCT02614612Phase 1
• Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
• Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaCompletedNCT02614495Phase 2
• Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum MalariaCompletedNCT02614404Phase 1
• A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal CancersCompletedNCT02613650Phase 1
• Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
• A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)CompletedNCT02612558Phase 2
• Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.WithdrawnNCT02611908Phase 1
• Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell TransplantCompletedNCT02611063Phase 1
• UCB Proof of Concept Study in Patients With Primary Sjögren's SyndromeTerminatedNCT02610543Phase 2
• Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsCompletedNCT02610361Phase 1
• Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.CompletedNCT02610075Phase 1
• ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic TherapyCompletedNCT02609958Phase 2
• Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy SubjectsCompletedNCT02609139Phase 1
• TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedNCT02608411Phase 2
• [18F]FLT PET/CT in Rb+ Metastatic Breast CancerActive, not recruitingNCT02608216Phase 1
• A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial CarcinomaTerminatedNCT02608125Phase 1
• A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateCompletedNCT02608034Phase 1
• Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsTerminatedNCT02607813Phase 1
• Regorafenib in GIST With Secondary C-KIT Exon 17 MutationCompletedNCT02606097Phase 2
• Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS MetastasisCompletedNCT02605746Early Phase 1
• Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)WithdrawnNCT02605694Phase 2
• Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Active, not recruitingNCT02605486Phase 1/2
• A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid TumorsTerminatedNCT02605083Phase 1/2
• Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal CancerTerminatedNCT02605044Phase 3
• Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node MetastasesActive, not recruitingNCT02603679Phase 2
• Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal FunctionCompletedNCT02603497Phase 1
• Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
• A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.TerminatedNCT02601378Phase 1
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorTerminatedNCT02601274Phase 1

← Protein Kinase Inhibitors overview